Oncocorner

Online Course
on demand

Mar
2021

Molecular Diagnostics and Genomics in Breast Cancer

Chairs: M.S. Aapro, CH - J. Gligorov, FR

BACKGROUND
The main common feature of cancer cells is their ability to escape to homeostatic regulation mechanisms of living. In a sense giving them immortality, causing in the absence of treatment the death of the organism, which is their origin. The exponential knowledge of the biology of cancer and the phenomenal capacity of synthesis of new treatments and diagnostic tools have opened up the prospect of a precision medicine in oncology that requires regular and frequent updating of our knowledge.
This knowledge concerns both the intrinsic prognosis of the disease, as the prediction value of therapeutic approaches that in fact becomes increasingly “personalized”. This course aims to take stock of current and future tools that help us optimize the care of patients with breast cancer.

LEARNING OBJECTIVES

Improve breast cancer patients care: value and clinical utility of prediction of CT benefit for early stage breast cancer patients
Practicing through case discussions

CME ACCREDITATION CERTIFICATES

Participants will be issued a certificate of attendance (minimum attendance: 75% of the entire course). An online evaluation questionnaire and learning assessment test will need to be completed in order to get the certficate that will be issued by email.

Application for CME recognition has been submitted to the Accreditation Council of Oncology in Europe (ACOE) and 8 CME credits have been granted to this event. The American Medical Association (AMA) and the Accreditation Council for Continuous Medical Education (ACCME) designate this type of educational activity for a maximum of 1 AMA PRA category 1 credits per hour of activity.

ACKNOWLEDGEMENTS

Sharing Progress in Cancer Care wishes to extend its appreciation to Daiichi Sankyo, Exact Sciences and Pfizer for having granted their participation and support to the Course.

01/03/2021 15:45 CET

Welcome and introduction

Chair: Matti Aapro, CH

Chair: Joseph Gligorov, FR

01/03/2021 15:50 CET

Optimize patient management in breast cancer: guiding adjuvant treatment decisions/

Expert: Mark Verrill, UK

01/03/2021 16:05 CET

Clinical utility of multigene assays in early breast cancer

01/03/2021 16:25 CET

Who to test with multigene assay: treatment algorithms – specific patient profiles (lobular; premenopausal CT decisions)

01/03/2021 17:05 CET

Discussion and Q&A

Chair: Matti Aapro, CH

Chair: Joseph Gligorov, FR

Expert: Anna Batistatou, GR

Expert: Francesco Cognetti, IT

Expert: Christos Markopoulos, GR

Expert: Ulrike Nitz, DE

Expert: Mark Verrill, UK

02/03/2021 15:45 CET

Welcome and introduction

02/03/2021 15:50 CET

Roundtable: Evidence based assessment of diagnostic tests: criteria for a health technology assessment – why outcomes of HTA decisions can be different…?

02/03/2021 16:20 CET

The essential pathology testing needed for breast cancer, quality control

Expert: Anna Batistatou, GR

02/03/2021 16:40 CET

What tests to ask for and what clinical implications in "TRIPLE NEGATIVE" BrCa”

Expert: Nadia Harbeck, DE

02/03/2021 16:55 CET

The patient advocacy perspective

Expert: Marzia Zambon, IT

02/03/2021 17:25 CET

Discussion and Q&A

Chair: Matti Aapro, CH

Chair: Joseph Gligorov, FR

Expert: Anna Batistatou, GR

Expert: Nadia Harbeck, DE

Expert: Ulrike Nitz, DE

Expert: Pascal Pujol, FR

Expert: Mark Verrill, UK

Expert: Marzia Zambon, IT

03/03/2021 17:20 CET

Group session: Patient Case discussion on multigene assays in early breast cancer: who to test and how to deal with the results?

Case 1: 1 patient 29 years HR+, HER2- pN0 with low-clinical risk
Case 2: 1 patient 73 years HR+, HER2- pN1 with high-clinical risk
Case 3: 1 patient 45 years HR+, HER2- pN0 with intermediate-clinical risk
Case 4: 1 patient 55 years HR+, HER2- pN0 with intermediate-clinical risk

03/03/2021 17:20 CET

Group 1

Expert: Joseph Gligorov, FR

Expert: Riccardo Masetti, IT

Expert: Elzbieta Senkus, PL

Expert: Zsuzsanna Varga, CH

03/03/2021 17:20 CET

Group 2

Expert: Matti Aapro, CH

Expert: Christos Markopoulos, GR

Expert: Miguel Martin, ES

Expert: Giancarlo Pruneri, IT

03/03/2021 18:40 CET

Panellists case discussion summary and Q&A

Chair: Matti Aapro, CH

Chair: Joseph Gligorov, FR

Expert: Christos Markopoulos, GR

Expert: Riccardo Masetti, IT

Expert: Ulrike Nitz, DE

Expert: Giancarlo Pruneri, IT

Expert: Elzbieta Senkus, PL

Expert: Zsuzsanna Varga, CH

04/03/2021 15:45 CET

Advanced breast cancer (PART 1) - Welcome and introduction

04/03/2021 15:50 CET

DNA Methylation

Expert: Romano Danesi, IT

04/03/2021 16:10 CET

NGS impact or not in breast cancer

Expert: Fabrice André, FR

04/03/2021 16:30 CET

Alpelisib what to test

04/03/2021 17:15 CET

Discussion and Q&A

Chair: Matti Aapro, CH

Chair: Joseph Gligorov, FR

Expert: Fabrice André, FR

Expert: Romano Danesi, IT

Expert: Frédérique Penault-Llorca, FR

Expert: Elzbieta Senkus, PL

05/03/2021 15:45 CET

Advanced breast cancer (PART 2) - Welcome and introduction

05/03/2021 15:50 CET

Parp inhibitors what to test

05/03/2021 16:20 CET

Immunotherapy: what to test

05/03/2021 16:50 CET

HER-2 alterations not defined as ASCO CAP HER-2 positivity

05/03/2021 17:35 CET

Discussion, Q&A and Closure

Chair: Matti Aapro, CH

Chair: Joseph Gligorov, FR

Expert: Francesco Cognetti, IT

Expert: Ulrike Nitz, DE

Expert: Frédérique Penault-Llorca, FR

Expert: Pascal Pujol, FR

Matti Aapro

Sharing Progress in Cancer Care and Clinique de Genolier, Bellinzona and Genolier, Switzerland

Fabrice André

Gustave Roussy Institute, Villejuif, France

Anna Batistatou

University of Ioannina, Ioannina, Greece

Francesco Cognetti

Istituto Nazionale Tumori Regina Elena, Rome, Italy

Romano Danesi

University of Pisa, Pisa, Italy

Joseph Gligorov

Hospital Tenon Ap-Hp, Paris, France

Nadia Harbeck

Breast Center, LMU University Hospital, Munich, Germany

Christos Markopoulos

Medical School, National University of Athens, Athens, Greece

Miguel Martin

Hospital General Universitario Gregorio Marañón, Madrid, Spain

Riccardo Masetti

Università Cattolica di Roma, Rome, Italy

Ulrike Nitz

Johanniter Hospital Bethesda, Mönchengladbach, Germany

Frédérique Penault-Llorca

Jean Perrin Center, Clermont-Ferrand, France

Giancarlo Pruneri

Fondazione IRCCS, Istituto Nazionale Tumori and University of Milan, Milan, Italy

Pascal Pujol

Centre Hospitalier Universitaire de Montpellier, Montpellier, France

Elzbieta Senkus

Medical University of Gdansk, Gdansk, Poland

Zsuzsanna Varga

University Hospital Zurich, Zurich, Switzerland

Mark Verrill

Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, United Kingdom

Marzia Zambon

EUROPA DONNA - The European Breast Cancer Coalition, Milan, Italy

Under the auspices of